| Title |
Delamanid expanded access novel treatment of drug resistant tuberculosis
|
|---|---|
| Published in |
Infection and Drug Resistance, October 2015
|
| DOI | 10.2147/idr.s62119 |
| Pubmed ID | |
| Authors |
Roxana Rustomjee, Alimuddin Zumla |
| Abstract |
Tuberculosis (TB) remains a global emergency and is one of the most common infectious disease causes of death in developing countries. Current treatment regimens for multi-drug resistant TB are associated with low treatment success rates, are toxic, and require long duration of treatment. The need for shorter and more effective treatment regimens is urgent. Delamanid (Deltyba, or formerly known as OPC-67683) is a new dihydro-imidazooxazole anti-TB drug active against resistant forms of pulmonary TB. Delamanid kills Mycobacterium tuberculosis by inhibiting the synthesis of mycolic acids required for cell wall synthesis. Whilst delamanid has been included in the WHO Model List of Essential Medicine by the World Health Organization Expert Committee on Selection and Use of Essential Medicines and in international guidance for the treatment of multi-drug resistant TB since April 2014, its access in countries with the greatest need, has proven challenging. This review provides an update on currently available clinical safety and efficacy data on delamanid and offers a discussion on research priorities and recommendations for expedited, expanded access. |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 1% |
| Unknown | 67 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 13% |
| Student > Ph. D. Student | 8 | 12% |
| Researcher | 7 | 10% |
| Student > Bachelor | 7 | 10% |
| Other | 5 | 7% |
| Other | 13 | 19% |
| Unknown | 19 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 32% |
| Chemistry | 5 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Nursing and Health Professions | 3 | 4% |
| Other | 11 | 16% |
| Unknown | 19 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2015.
All research outputs
#20,298,249
of 22,835,198 outputs
Outputs from Infection and Drug Resistance
#1,260
of 1,654 outputs
Outputs of similar age
#230,584
of 274,933 outputs
Outputs of similar age from Infection and Drug Resistance
#6
of 7 outputs
Altmetric has tracked 22,835,198 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,654 research outputs from this source. They receive a mean Attention Score of 3.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,933 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one.